» Articles » PMID: 12738676

Rapid and Complete Donor Chimerism in Adult Recipients of Unrelated Donor Umbilical Cord Blood Transplantation After Reduced-intensity Conditioning

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2003 May 10
PMID 12738676
Citations 116
Authors
Affiliations
Soon will be listed here.
Abstract

Reduced-intensity conditioning may reduce transplantation-related mortality in high-risk adults undergoing hematopoietic transplantation. We investigated unrelated donor umbilical cord blood (UCB) transplantation after such conditioning in 43 patients (median age, 49.5 years; range, 22-65 years) with a primary end point of donor engraftment. The first 21 patients received busulfan 8 mg/kg, fludarabine 200 mg/m2, and 200 cGy of total body irradiation (Bu/Flu/TBI). Subsequent patients (n = 22) received cyclophosphamide 50 mg/kg, fludarabine 200 mg/m2, and 200 cGy TBI (Cy/Flu/TBI). UCB grafts (93%) were 1-2 HLA antigen-mismatched with the recipient and contained a median cryopreserved cell dose of 3.7 x 107 (range, 1.6 x 107-6.0 x 107) nucleated cells per kilogram of recipient body weight (NC/kg). Graft versus host disease (GVHD) prophylaxis was cyclosporin A to day 180 plus mycophenolate mofetil to day 30. The cumulative incidence of sustained donor engraftment was 76% (95% confidence interval [CI], 56%-96%) for Bu/Flu/TBI recipients and 94% (95% CI, 84%-100%) for Cy/Flu/TBI recipients. The median day of neutrophil recovery (at least 0.5 x 109/L) for engrafting Bu/Flu/TBI recipients was 26 days (range, 12-30 days) and for Cy/Flu/TBI recipients was 9.5 days (range, 5-28 days). Incidence of grades III-IV acute GVHD was 9% (95% CI, 1%-17%), and survival at 1 year was 39% (95% CI, 23%-56%). These data demonstrate that 0-2 antigen mismatched UCB is sufficient to engraft most adults after reduced-intensity conditioning and is associated with a low incidence of severe acute GVHD.

Citing Articles

Development of an umbilical cord blood transplantation-specific nonrelapse mortality risk assessment score.

Okada Y, Usui Y, Hayashi H, Nishikubo M, Toubai T, Uchida N Blood Adv. 2024; 8(6):1359-1368.

PMID: 38163321 PMC: 10945135. DOI: 10.1182/bloodadvances.2023011837.


Umbilical Cord Blood Transplantation: Connecting Its Origin to Its Future.

Sanchez-Petitto G, Rezvani K, Daher M, Rafei H, Kebriaei P, Shpall E Stem Cells Transl Med. 2023; 12(2):55-71.

PMID: 36779789 PMC: 9985112. DOI: 10.1093/stcltm/szac086.


Cord-Blood Engraftment Using an Enhanced Dual-Conditioning Regimen for Malignant Hematologic Diseases.

Ding J, Fang Y, Zhou R, Gu Y, Du S, Lu Q Cell Transplant. 2022; 31:9636897211070238.

PMID: 35073786 PMC: 8793423. DOI: 10.1177/09636897211070238.


Engraftment of Double Cord Blood Transplantation after Nonmyeloablative Conditioning with Escalated Total Body Irradiation Dosing to Facilitate Engraftment in Immunocompetent Patients.

Brunstein C, DeFor T, Fuchs E, Karanes C, McGuirk J, Rezvani A Transplant Cell Ther. 2021; 27(10):879.e1-879.e3.

PMID: 34273598 PMC: 8858593. DOI: 10.1016/j.jtct.2021.07.006.


Microfluidics as efficient technology for the isolation and characterization of stem cells.

Aghlmandi A, Nikshad A, Safaralizadeh R, Warkiani M, Aghebati-Maleki L, Yousefi M EXCLI J. 2021; 20:426-443.

PMID: 33746671 PMC: 7975637. DOI: 10.17179/excli2020-3028.